Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Servier is again reaching into its purse, this time looking to bolster its neuro pipeline with Kaerus Bioscience's fragile X syndrome candidate. Under the…
Kaerus Bioscience today announced that it has entered into a definitive agreement with Servier for the acquisition of KER-0193, a novel oral BK channel…
French drugmaker Servier is expanding beyond oncology with the acquisition of Kaerus Bioscience's Fragile X syndrome candidate KER-0193 for up to $450 million.…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Servier agreed to acquire KER-0193, a Phase 1-completed potential treatment for Fragile X syndrome, from Kaerus Bioscience for total deal value up to $450M including upfront and development/commercial earn-out payments. First neurology asset acquisition; Orphan and Rare Pediatric drug designations.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Servier / Kaerus Bioscience Ltd. (this deal) | 2025 | $450M | — |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| Servier / Edgewise Therapeutics, Inc. | 2026 | $2.6B | 75 |
| Servier / Symphogen A/S | 2006 | — | 66 |
| Servier / Symphogen A/S | 2020 | — | — |
| Servier / Pieris Pharmaceuticals, Inc. | 2017 | $1.7B | — |
← Browse all deals · How we score deals
More: 2025 deals · Servier deals · Rare Disease deals